2022
Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer
Tarantino P, Curigliano G, Parsons HA, Lin NU, Krop I, Mittendorf EA, Waks A, Winer EP, Tolaney SM. Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer. JAMA Oncology 2022, 8: 629-635. PMID: 35024766, DOI: 10.1001/jamaoncol.2021.6597.Peer-Reviewed Original ResearchConceptsErbB2-positive metastatic breast cancerMetastatic breast cancerPopulation of patientsBreast cancerDe novo metastaticErb-b2 receptor tyrosine kinase 2High ERBB2 expressionCurrent treatment algorithmsHigh-dose chemotherapyLong-term respondersFraction of patientsAntitumor immune activationReceptor tyrosine kinase 2Quality of lifeOverall survivalSystemic treatmentTrastuzumab deruxtecanPathologic featuresTreatment algorithmFrontline treatmentImmune activationBiologic treatmentPathologic termsDisease burdenLong-term benefits
2005
Quality of life among patients with Stage II and III breast carcinoma randomized to receive high‐dose chemotherapy with autologous bone marrow support or intermediate‐dose chemotherapy
Peppercorn J, Herndon J, Kornblith AB, Peters W, Ahles T, Vredenburgh J, Schwartz G, Shpall E, Hurd DD, Holland J, Winer E, Group T. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high‐dose chemotherapy with autologous bone marrow support or intermediate‐dose chemotherapy. Cancer 2005, 104: 1580-1589. PMID: 16118805, DOI: 10.1002/cncr.21363.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBone Marrow TransplantationBreast NeoplasmsCarmustineChemotherapy, AdjuvantCisplatinCombined Modality TherapyCyclophosphamideDose-Response Relationship, DrugFemaleHumansMiddle AgedNeoplasm StagingQuality of LifeSurvival RateTime FactorsTransplantation, AutologousConceptsQuality of lifeFunctional Living Index-CancerPositive lymph nodesHigh-dose chemotherapySymptom Distress ScaleBreast carcinomaHDC armLymph nodesQOL scoresAutologous bone marrow supportAutologous stem cell supportMcCorkle Symptom Distress ScaleMultiple positive lymph nodesAutologous bone marrow transplantationIntensive adjuvant therapyBone marrow supportHigh-dose cyclophosphamideStem cell supportTotal QOL scoreBone marrow transplantationAdjuvant chemotherapyAdjuvant settingAdjuvant therapyMarrow supportIndex cancer
2001
Quality of Life Issues Among Women Undergoing High-Dose Chemotherapy for Breast Cancer
Partridge A, Bunnell C, Winer E. Quality of Life Issues Among Women Undergoing High-Dose Chemotherapy for Breast Cancer. Breast Disease 2001, 14: 41-50. PMID: 15687635, DOI: 10.3233/bd-2001-14106.Peer-Reviewed Original ResearchHigh-dose chemotherapyOverall QoLPhysical functioningBreast cancerAutologous stem cell supportHigh-dose therapyStem cell supportDose chemotherapyTransplant resultsPatients' qualityConsiderable symptomsQoL findingsRole functioningTransient impairmentChemotherapyCell supportQoLSexual functioningLife issuesPatientsCognitive functioningTherapySymptomsCancerAdditional research
1999
Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support
Winer E, Lindley C, Hardee M, Sawyer W, Brunatti C, Borstelmann N, Peters W. Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support. Psycho-Oncology 1999, 8: 167-176. PMID: 10335560, DOI: 10.1002/(sici)1099-1611(199903/04)8:2<167::aid-pon354>3.0.co;2-s.Peer-Reviewed Original ResearchConceptsFunctional Living Index-CancerHigh-dose chemotherapyQuality of lifeAutologous bone marrow supportBone marrow supportSymptom Distress ScaleDose chemotherapyBreast cancerMarrow supportSexual functioningMajority of patientsBreast cancer patientsLong-term outcomesTreatment of patientsMore yearsFLIC scoresTransplant supportIndex cancerRecurrent diseaseAssessment of qualityMedian timeCancer patientsSexual functionClinical trialsSevere symptoms
1993
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.
Peters W, Ross M, Vredenburgh J, Meisenberg B, Marks L, Winer E, Kurtzberg J, Bast R, Jones R, Shpall E. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. Journal Of Clinical Oncology 1993, 11: 1132-43. PMID: 8501500, DOI: 10.1200/jco.1993.11.6.1132.Peer-Reviewed Original ResearchConceptsAutologous bone marrow supportPrimary breast cancerHigh-risk primary breast cancerBone marrow supportEvent-free survivalBreast cancerMarrow supportLymph nodesActuarial event-free survivalMore axillary lymph nodesHigh-dose consolidationIIIB breast cancerStandard-dose cyclophosphamideTherapy-related mortalityAdjuvant chemotherapy trialsHigh-dose cyclophosphamideAxillary lymph nodesHigh-dose chemotherapyMore lymph nodesAdjuvant chemotherapy treatmentAdjuvant therapyChemotherapy trialsStudy patientsConcurrent cancerStage IIA